

Texas Department of Insurance

Division of Workers' Compensation - Medical Fee Dispute Resolution (MS-48) 7551 Metro Center Drive, Suite 100, Austin, Texas 78744-1645 (512) 804-4000 | F: (512) 804-4811 | (800) 252-7031 | TDI.texas.gov | @TexasTDI

# MEDICAL FEE DISPUTE RESOLUTION FINDINGS AND DECISION

## **GENERAL INFORMATION**

**Requestor Name** Memorial Compounding Pharmacy **Respondent Name** American Zurich Insurance Co

MFDR Tracking Number

**Carrier's Austin Representative** 

M4-21-0922-01

Box Number 19

**MFDR Date Received** 

February 2, 2021

#### **REQUESTOR'S POSITION SUMMARY**

Requestor's Position Summary: "The bill was audited in error and is being submitted back to the carrier for processing."

Amount in Dispute: \$232.55

## **RESPONDENT'S POSITION SUMMARY**

Respondent's Position Summary: "This bill is in line for payment per fee schedule. The Carrier will supplement this response upon completion."

Response Submitted by: Flahive Ogden & Latson

## SUMMARY OF FINDINGS

Dates of Service	Disputed Services	Amount In Dispute	Amount Due
November 23, 2020	Diclofenac Sodium 1% Gel	\$232.55	\$0.00

## FINDINGS AND DECISION

This medical fee dispute is decided pursuant to Texas Labor Code §413.031 and applicable rules of the Texas Department of Insurance, Division of Workers' Compensation.

#### Background

- 1. 28 Texas Administrative Code §133.307 sets out the procedures for resolving medical fee disputes.
- 2. 28 Texas Administrative Code §134.530 sets out the guidelines for pharmacy services.

#### Issues

Did the requestor support compliance with applicable DWC rule?

### **Findings**

The requestor is seeking reimbursement of Diclofenac Sodium 1% Gel dispensed on November 23, 2020.

28 TAC §134.530 (b) (1) (A) states in pertinent part preauthorization is only required for drugs identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp (ODG) / Appendix A. Review of Appendix A found the following:

NSAIDs	Diclofenac sodium	Dyloject	No	Ν
NSAIDs	Diclofenac sodium	Voltaren ®	Yes	Y
NSAIDs	Diclofenac sodium ER	Voltaren-XR ®	Yes	Ν
NSAIDs	Diclofenac sodium topical	Pennsaid ®	Yes	N

Insufficient evidence was found to support the medication in dispute received the required prior authorization or did not require prior authorization.

No payment is recommended.

#### **Conclusion**

In resolving disputes over reimbursement for medically necessary health care to treat a compensable injury, the role of DWC is to adjudicate payment following Texas laws and DWC rules. The findings in this decision are based on the evidence available at the time of review. Even though not all the evidence was discussed, it was considered.

For the reasons above the requestor has not established payment is due. As a result, the amount ordered is \$0.00.

#### ORDER

Based on the submitted information, pursuant to Texas Labor Code Section 413.031, the division hereby determines the requestor is entitled to \$0.00 additional reimbursement for the services in dispute.

#### Authorized Signature

Signature

Medical Fee Dispute Resolution Officer

May 14, 2021

Date

## YOUR RIGHT TO APPEAL

Either party to this medical fee dispute has a right to seek review of this decision in accordance with Rule §133.307, effective May 31, 2012, *37 Texas Register 3833*, applicable to disputes filed on or after June 1, 2012.

A party seeking review must submit a **Request to Schedule a Benefit Review Conference to Appeal a Medical Fee Dispute Decision** (form **DWC045M**) in accordance with the instructions on the form. The request must be received by DWC within **twenty** days of your receipt of this decision. The request may be faxed, mailed or personally delivered to DWC using the contact information listed on the form or to the field office handling the claim.

The party seeking review of the MFDR decision shall deliver a copy of the request to all other parties involved in the dispute at the same time the request is filed. **Please include a copy of the** *Medical Fee Dispute Resolution Findings and Decision* together with any other required information specified in 28 TAC §141.1(d).

Si prefiere hablar con una persona en español acerca de ésta correspondencia, favor de llamar a 512-804-4812.